Despite considerable progress in genome-and proteome-based high-throughput screening
methods and in rational drug design, the increase in approved drugs in the past decade did …

The majority of human cancers acquire mutations that abrogate the p53 tumor suppressor
network and, as a consequence, p53 is one of the most extensively studied proteins in …

The occurrence of idiosyncratic drug hepatotoxicity is a major problem in all phases of
clinical drug development and the most frequent cause of post-marketing warnings and …

The liver is the center for drug and xenobiotic metabolism, which is influenced most with
medication/xenobiotic-mediated toxic activity. Drug-induced hepatotoxicity is common and …

Drug-induced liver injury (DILI) is a leading cause of drugs failing during clinical trials and
being withdrawn from the market. Comparative analysis of drugs based on their DILI …

The combination of high aminotransferases (hepatocellular injury) and jaundice has been
reported to lead to a mortality rate of 10% to 50% for different drugs, a phenomenon known …

Drug-induced liver injury (DILI) has become a leading cause of severe liver disease in
Western countries and therefore poses a major clinical and regulatory challenge. Whereas …

To develop and validate a practical, in vitro, cell-based model to assess human
hepatotoxicity potential of drugs, we used the new technology of high content screening …

Drug-induced hepatotoxicity is a frequent cause of liver injury. The predominant clinical
presentation is acute hepatitis and/or cholestasis, although almost any clinical pathological …

Studies of acute liver failure from drugs have included cases mostly attributed to
acetaminophen (APAP) but have reported limited data on other drugs. We used the United …